Compare Panacea Biotech with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs ABBOTT INDIA - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH ABBOTT INDIA PANACEA BIOTECH/
ABBOTT INDIA
 
P/E (TTM) x 8.9 47.1 18.8% View Chart
P/BV x 3.5 15.2 22.7% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 PANACEA BIOTECH   ABBOTT INDIA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-19
ABBOTT INDIA
Mar-19
PANACEA BIOTECH/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs3548,834 4.0%   
Low Rs1385,458 2.5%   
Sales per share (Unadj.) Rs74.61,731.1 4.3%  
Earnings per share (Unadj.) Rs6.7211.9 3.2%  
Cash flow per share (Unadj.) Rs15.5219.9 7.0%  
Dividends per share (Unadj.) Rs065.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs57.2945.2 6.1%  
Shares outstanding (eoy) m61.2521.25 288.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.34.1 79.9%   
Avg P/E ratio x36.833.7 109.2%  
P/CF ratio (eoy) x15.932.5 48.8%  
Price / Book Value ratio x4.37.6 56.9%  
Dividend payout %030.7 0.0%   
Avg Mkt Cap Rs m15,061151,848 9.9%   
No. of employees `0002.33.5 66.4%   
Total wages/salary Rs m1,4714,356 33.8%   
Avg. sales/employee Rs Th1,973.610,555.5 18.7%   
Avg. wages/employee Rs Th635.61,249.9 50.9%   
Avg. net profit/employee Rs Th176.81,292.2 13.7%   
INCOME DATA
Net Sales Rs m4,56736,786 12.4%  
Other income Rs m451,133 4.0%   
Total revenues Rs m4,61237,919 12.2%   
Gross profit Rs m2,0306,047 33.6%  
Depreciation Rs m540169 319.1%   
Interest Rs m1,04823 4,659.1%   
Profit before tax Rs m4866,989 7.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m772,485 3.1%   
Profit after tax Rs m4094,503 9.1%  
Gross profit margin %44.416.4 270.3%  
Effective tax rate %15.935.6 44.6%   
Net profit margin %9.012.2 73.2%  
BALANCE SHEET DATA
Current assets Rs m2,41527,610 8.7%   
Current liabilities Rs m9,0778,569 105.9%   
Net working cap to sales %-145.951.8 -281.9%  
Current ratio x0.33.2 8.3%  
Inventory Days Days6560 108.1%  
Debtors Days Days7127 258.8%  
Net fixed assets Rs m8,3331,057 788.5%   
Share capital Rs m61213 28.8%   
"Free" reserves Rs m3,44319,873 17.3%   
Net worth Rs m3,50420,086 17.4%   
Long term debt Rs m4610-   
Total assets Rs m13,75529,409 46.8%  
Interest coverage x1.5311.6 0.5%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.31.3 26.5%   
Return on assets %10.615.4 68.8%  
Return on equity %11.722.4 52.1%  
Return on capital %38.734.9 110.9%  
Exports to sales %20.90-   
Imports to sales %8.10-   
Exports (fob) Rs m954NA-   
Imports (cif) Rs m372NA-   
Fx inflow Rs m1,203369 326.1%   
Fx outflow Rs m4674,918 9.5%   
Net fx Rs m736-4,549 -16.2%   
CASH FLOW
From Operations Rs m1,0494,991 21.0%  
From Investments Rs m-54-2,570 2.1%  
From Financial Activity Rs m-1,011-1,428 70.8%  
Net Cashflow Rs m-20993 -2.0%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.6 7.9 7.6%  
FIIs % 1.3 0.1 1,300.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 17.1 138.0%  
Shareholders   10,259 18,270 56.2%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Bloodbath on Dalal Street: 6 Reasons Why Sensex Nosedived 1,939 Points Today(Closing)

Indian share markets witnessed a sharp sell-off today and ended deep in the red.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 26, 2021 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS